NCT05079425View on ClinicalTrials.gov

A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions

Healthy

Interventions

DRUG

NXC736

Oral administration

DRUG

Placebo

Oral administration

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

NEXTGEN Bioscience

All Listed Sponsors

lead

NEXTGEN Bioscience

INDUSTRY